Bausch Health ehemals VALEANT PHARMA Allergan-Übernahme beflügelt (Seite 255)
eröffnet am 30.04.14 17:10:46 von
neuester Beitrag 10.04.24 21:16:45 von
neuester Beitrag 10.04.24 21:16:45 von
Beiträge: 4.274
ID: 1.193.944
ID: 1.193.944
Aufrufe heute: 0
Gesamt: 389.576
Gesamt: 389.576
Aktive User: 0
ISIN: CA0717341071 · WKN: A2JQ1X · Symbol: BHC
8,6000
USD
-0,69 %
-0,0600 USD
Letzter Kurs 02:04:00 NYSE
Neuigkeiten
11.04.24 · Accesswire  |
11.04.24 · Accesswire |
03.04.24 · Accesswire |
02.04.24 · Accesswire |
Werte aus der Branche Pharmaindustrie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 3,5800 | +922,86 | |
| 1,0400 | +48,57 | |
| 0,5400 | +38,46 | |
| 5,4000 | +27,06 | |
| 1,9900 | +26,75 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 24,000 | -20,00 | |
| 28,18 | -32,62 | |
| 100,00 | -37,50 | |
| 3,6400 | -38,62 | |
| 0,5660 | -40,42 |
Beitrag zu dieser Diskussion schreiben
FeedbackPaulson & Co. Inc. buys shares of VRX / Valeant Pharmaceuticals International, Inc.
https://fintel.io/soh/us/vrx/paulsonDer Herr Paulson hat auch Geld investiert.
Antwort auf Beitrag Nr.: 55.208.987 von marty44 am 26.06.17 19:49:14knapp daneben 17,08 USD
Antwort auf Beitrag Nr.: 55.208.480 von marty44 am 26.06.17 18:52:11
Das ist wohl leider noch nicht deutlich genug. Zufrieden können wir trotzdem sein
Zitat von marty44: Wenn ich es recht sehe, dann sind wir nun auch über die Hochs vom Februar hinaus.
Das ist wohl leider noch nicht deutlich genug. Zufrieden können wir trotzdem sein
OPTIONS TRADERS BLAST VALEANT, FACEBOOK STOCKS
http://www.schaeffersresearch.com/content/options/2017/06/26…
Ich tippe mal auf einen SK von 17,17 USD.
Trading Spotlight
VALEANT PHARMACEUTICALS INTERNATIONAL, INC. (VRX)
http://appsforpcdaily.com/2017/06/valeant-pharmaceuticals-in… 3 Cheap Healthcare Stocks You Can Buy Right Now
https://www.fool.com/investing/2017/06/26/3-cheap-healthcare…...
Valeant's stock is on the mend, but can it keep up the momentum?
Valeant's stock is trading at a price-to-sales ratio of 0.6. That's not a typo. The unfortunate part is that this fire-sale valuation might actually be warranted.
Long story short, Valeant's shares collapsed after the company got its hand caught in the mousetrap that is the drug-pricing controversy. Valeant's core business model, after all, has been to acquire drugs already on the market, reprice them at jaw-dropping amounts, and subsequently relaunch them. When the company drew flak from payers and Congress for this questionable practice, Valeant imploded because it also took on a mountain of debt to employ this rather aggressive growth-by-acquisition strategy.
Valeant is struggling to answer a key question about its future: How will it solve its debt problem and return to growth at the same time? Over the past year, the drugmaker has been divesting assets such as the advanced prostate cancer therapy Provenge and attempting to pay down debt at the same time to allay investors' fears about this overarching issue.
However, these efforts haven't changed the company's fundamental outlook. Valeant, after all, still owes a whopping $28 billion, and its interest expense is moving in the wrong direction -- despite an overall lower debt load.
So while the drugmaker's shares have been rallying of late -- gaining 29% in the past week alone -- because of news that hedge-fund manager John Paulson has joined the board, Valeant's long-term value proposition remains a mystery for the most part. In fact, the company could end up divesting multiple core assets to put its debt problems to bed once and for all -- but such a move would also alter its underlying growth prospects.
All told, Valeant is cheap, but this picture may change dramatically as its asset divestiture plans continue to unfold. So this beaten-down healthcare stock is arguably a buy only for investors with a strong appetite for risk.
...
Valeant Pharma (VRX) Gains Tied to Speculation of Debt-for-Equity Swap - Evercore ISI's Raffat
https://www.streetinsider.com/Analyst+Comments/Valeant+Pharm…
Wenn ich es recht sehe, dann sind wir nun auch über die Hochs vom Februar hinaus. 
Durchsuchen
Bausch Health ehemals VALEANT PHARMA Allergan-Übernahme beflügelt
